Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VULCANize2: Chemoradiation vs neoadjuvant chemotherapy plus surgery in locally advanced vulvar cancer
2022-502685-25-00Phase 3Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of carboplatin, paclitaxel and cisplatin in vulvar squamous cell carcinoma (VSCC) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Loco-regional control at 2 years. Planned start Jan 2024; status: authorised.
02
Drugs
carboplatinpaclitaxelcisplatin
03
Conditions
vulvar squamous cell carcinoma (VSCC)
Beyond the preview
Go deeper on 2022-502685-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502685-25-00.